Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 3/20 | 0.40 |
| ▸ | IGF1R | P08069 | 3/20 | 0.40 |
| ▸ | STK3 | Q13188 | 3/20 | 0.40 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541168 | 0.92 | KDR (0.48) | SLC2A1KDRAURKBAURKACDK19 | |
| SCHEMBL3541687 | 0.89 | KDR (0.53) | SLC2A1KDRAURKBAURKACDK19 | |
| SCHEMBL3537310 | 0.88 | IGF1R (0.48) | SLC2A1KDRAURKBAURKACDK19 | |
| SCHEMBL3537903 | 0.84 | INSR (0.51) | SLC2A1KDRAURKBAURKACDK19 | |
| SCHEMBL14515550 | 0.83 | SLC2A1 (0.46) | SLC2A1KDRAURKBAURKACDK19 | |
| SCHEMBL3536782 | 0.81 | SLC2A1 (0.45) | SLC2A1KDRAURKBMAPK8MAPK9 | |
| SCHEMBL3546062 | 0.81 | KDR (0.55) | SLC2A1KDRAURKBAURKACDK19 | |
| SCHEMBL3537938 | 0.81 | MEN1 (0.47) | MEN1POLBKMT2AL3MBTL1 | |
| SCHEMBL3537500 | 0.81 | EGFR (0.46) | SLC2A1KDRAURKBMAPK8MAPK9 | |
| SCHEMBL3537602 | 0.80 | EGFR (0.49) | SLC2A1KDRAURKBAURKACDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971606-B1 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-04-24 | — | — | EP | claimed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | claimed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | claimed |
| EP-1971606-B1 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | ERBB2, ERBB3, ERBB4 | SLC2A1 3810/4885KDR 11/4885AURKB 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.